AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25542687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabivarin (10mg)
Number of subjects: 20
Study 25542687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22160847 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional triage method
Number of subjects: 40
Study 22160847 — intervention group
Group type: COMPARATOR
Intervention: AHA-recommended method
Number of subjects: 40
Study 22160847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 40
Study 20356583 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D transvaginal sonography
Number of subjects: 39
Study 18641116 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 123
Study 16180594 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) treatment
Number of subjects: 35
Study 16180594 — intervention group
Group type: COMPARATOR
Intervention: Therapist-supervised self-range of motion
Number of subjects: 35
Study 14642083 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid plus amoxicillin 1000mg bid and levofloxacin 200mg bid
Number of subjects: 85
Study 14642083 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 85
Study 10572788 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 0
Study 10572788 — intervention group
Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 0
Study 8545281 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate 600 mg/m2‐po daily for up to 2 years
Number of subjects: 437
Study 8545281 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide 1 gram/m2‐IV every 3 weeks for 2 years
Number of subjects: 437
Study 8545281 — intervention group
Group type: COMPARATOR
Intervention: observation only
Number of subjects: 437
Study 8545281 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 437
Study 8545281 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Number of subjects: 437
Study 8545281 — intervention group
Group type: EXPERIMENTAL
Intervention: adjuvant therapy (any)
Number of subjects: 437
Study 8545281 — intervention group
Group type: COMPARATOR
Intervention: extensive nodal disease (no adjuvant)
Number of subjects: 437
Study 1678550 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF-94482 400 mg at 0830 h
Number of subjects: 45
Study 1678550 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF-94482 400 mg at 1830 h
Number of subjects: 45
Study 1678550 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 0830 h
Number of subjects: 45
Study 1678550 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 1830 h
Number of subjects: 45
Study 1678550 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF-94482 200 mg or 300 mg at 0830 and 1830 h
Number of subjects: 45
Study 29549394 — intervention group
Group type: COMPARATOR
Intervention: Transobturator inside-out mid-urethral sling (TOT)
Number of subjects: 201
Study 29549394 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision needleless mini-sling (SIMS)
Number of subjects: 201
Study 27710241 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors (AI)
Number of subjects: 76
Study 27710241 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 76
Study 27710241 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination AI/GH
Number of subjects: 76
Study 27710241 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study 24423356 — intervention group
Group type: COMPARATOR
Intervention: Testosterone alone (n = 15)
Number of subjects: 32
Study 24423356 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and growth hormone (n = 17)
Number of subjects: 32
Study 22540970 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention consisting of several massage techniques, mobilizations, and local and global exercises.
Number of subjects: 24
Study 22540970 — intervention group
Group type: COMPARATOR
Intervention: Simple hand contact/touch to areas of pain (control group).
Number of subjects: 24
Study 20047544 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (30 mg/kg as a single dose)
Number of subjects: 306
Study 20047544 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (50 mg/kg/day in two divided doses for a minimum of 7 days)
Number of subjects: 306
Study 20047544 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin
Number of subjects: 306
Study 20047544 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 306
Study 20047544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 306
Study 18282630 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 4756
Study 18282630 — intervention group
Group type: EXPERIMENTAL
Intervention: National Cholesterol Education Program (NCEP) definition of Metabolic Syndrome
Number of subjects: 4756
Study 18282630 — intervention group
Group type: EXPERIMENTAL
Intervention: International Diabetes Federation (IDF) definition of Metabolic Syndrome
Number of subjects: 4756
Study 18282630 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO definition of Metabolic Syndrome
Number of subjects: 4756
Study 18282630 — intervention group
Group type: EXPERIMENTAL
Intervention: All definitions of Metabolic Syndrome
Number of subjects: 4756
Study 15647042 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 24
Study 15647042 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 24
Study 12860945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (1 mg three times a day administered subcutaneously)
Number of subjects: 80
Study 12860945 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (5 x 106 U three times a week subcutaneously)
Number of subjects: 80
Study 12860945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lanreotide and interferon alfa
Number of subjects: 80
Study 11310381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal HBV vaccine (20 mu gms) once a week for 6 weeks
Number of subjects: 85
Study 11310381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal HBV vaccine (20 mu gms) twice a week for 6 weeks
Number of subjects: 85
Study 11310381 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo (phase 2) in addition to HBV
Number of subjects: 85
Study 11310381 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 patients (receiving Epo)
Number of subjects: 85
Study 11310381 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 patients (not receiving Epo)
Number of subjects: 85
Study 11310381 — intervention group
Group type: EXPERIMENTAL
Intervention: Epo and twice weekly vaccine (group 2 of phase 2)
Number of subjects: 85
Study 8901851 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 1404
Study 1725554 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionibacterium granulosum KP‐45 (interferon inducer) + isoprinosine
Number of subjects: 0
Study 1725554 — intervention group
Group type: EXPERIMENTAL
Intervention: TFX (thymus extract) + isoprinosine
Number of subjects: 0
Study 1725554 — intervention group
Group type: COMPARATOR
Intervention: Isoprinosine only
Number of subjects: 0
Study 6643397 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam treatment
Number of subjects: 41
Study 6643397 — intervention group
Group type: COMPARATOR
Intervention: Natural history control (no immediate treatment)
Number of subjects: 41
Study 31282566 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal targets for mean arterial pressure, arterial oxygen and carbon dioxide partial pressures
Number of subjects: 120
Study 31282566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-normal targets for mean arterial pressure, arterial oxygen and carbon dioxide partial pressures
Number of subjects: 120
Study 31282566 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 120
Study 27154958 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed Chlamydia trachomatis infection
Number of subjects: 2401
Study 27154958 — intervention group
Group type: COMPARATOR
Intervention: No undiagnosed Chlamydia trachomatis infection
Number of subjects: 2401
Study 27154958 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic Chlamydia trachomatis infection
Number of subjects: 2401
Study 27154958 — intervention group
Group type: COMPARATOR
Intervention: No symptomatic Chlamydia trachomatis infection
Number of subjects: 2401
Study 27458407 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-session internet-based self-efficacy intervention
Number of subjects: 168
Study 27458407 — intervention group
Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 168
Study 24983798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Number of subjects: 56
Study 24983798 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 56
Study 24983798 — intervention group
Group type: COMPARATOR
Intervention: Control strategy
Number of subjects: 56
Study 21949007 — intervention group
Group type: EXPERIMENTAL
Intervention: tocilizumab 8 mg/kg every 4 weeks
Number of subjects: 619
Study 21949007 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 619
Study 19700134 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Patients
Number of subjects: 393
Study 19700134 — intervention group
Group type: EXPERIMENTAL
Intervention: Female HF Partners
Number of subjects: 393
Study 19700134 — intervention group
Group type: EXPERIMENTAL
Intervention: Male Partners
Number of subjects: 393
Study 19700134 — intervention group
Group type: EXPERIMENTAL
Intervention: RAND-36 Mental Health Domain
Number of subjects: 393
Study 19700134 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive Symptoms
Number of subjects: 393
Study 18269130 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm fluoride mouthrinse (100 ppm amine fluoride and 150 ppm sodium fluoride)
Number of subjects: 24
Study 18269130 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 24
Study 16286056 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir 10 mg once daily for 14 days
Number of subjects: 482
Study 16286056 — intervention group
Group type: COMPARATOR
Intervention: Rimantadine 100 mg once daily for 14 days (for influenza A) or placebo (for influenza B)
Number of subjects: 482
Study 12216096 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and gemcitabine (Arm A)
Number of subjects: 267
Study 12216096 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and vinorelbine (Arm B)
Number of subjects: 267
Study 12216096 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and gemcitabine (Arm C)
Number of subjects: 267
Study 12216096 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and vinorelbine (Arm D)
Number of subjects: 267
Study 12216096 — intervention group
Group type: COMPARATOR
Intervention: Historic control (not specified)
Number of subjects: 267
Study 10391957 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibody levels against 38 kDa mycobacterial antigen (measured using ELISA based kits)
Number of subjects: 200
Study 10391957 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons and patients with other conditions)
Number of subjects: 200
Study 7543113 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg testosterone buciclate (TB) injection
Number of subjects: 12
Study 7543113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg testosterone buciclate (TB) injection
Number of subjects: 12
Study 7543113 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (600 mg and 1200 mg TB)
Number of subjects: 12
Study 2702967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at 50 beats min‐1
Number of subjects: 18
Study 2702967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at 70 beats min‐1
Number of subjects: 18
Study 2702967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at 90 beats min‐1
Number of subjects: 18
Study 2702967 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk testing
Number of subjects: 18
Study 2702967 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly pedometer distance
Number of subjects: 18
Study 946937 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose skim milk (15 g lactose, 2.5 cups)
Number of subjects: 33
Study 946937 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lactose skim milk (7.5 g lactose, 2.5 cups)
Number of subjects: 33
Study 946937 — intervention group
Group type: COMPARATOR
Intervention: Regular skim milk (30 g lactose, 2.5 cups)
Number of subjects: 33
Study 946937 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g lactose in water (250 ml)
Number of subjects: 33
Study 946937 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk (500 ml) with 25 g lactose
Number of subjects: 33
Study 946937 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk (500 ml) with 25 g lactose
Number of subjects: 33
Study 946937 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g lactose in lactose-reduced skim (500 ml)
Number of subjects: 33
Study 946937 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk (500 ml) with 10 g lactose
Number of subjects: 33
Study 946937 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml)
Number of subjects: 33
Study 31404466 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week nicotine replacement therapy sample (NRTS) including gum/patch and brief advice lasting 10 minutes
Number of subjects: 100
Study 31404466 — intervention group
Group type: COMPARATOR
Intervention: Brief advice only (control)
Number of subjects: 100
Study 31422079 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term proton pump inhibitors (PPIs) therapy (>12 months, n = 85)
Number of subjects: 203
Study 31422079 — intervention group
Group type: COMPARATOR
Intervention: No proton pump inhibitors (non-PPI group, n = 118)
Number of subjects: 203
Study 28358634 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 3 mg/kg IV
Number of subjects: 9
Study 28358634 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 5 mg/kg IV
Number of subjects: 9
Study 28358634 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 10 mg/kg IV
Number of subjects: 9
Study 25010405 — intervention group
Group type: EXPERIMENTAL
Intervention: Steep Ramp Test (SRT)
Number of subjects: 40
Study 23631544 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy (mean duration: 39 months, mean dose: 234 sessions)
Number of subjects: 0
Study 23631544 — intervention group
Group type: COMPARATOR
Intervention: Psychodynamic therapy (mean duration: 34 months, mean dose: 88 sessions)
Number of subjects: 0
Study 23631544 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic therapy
Number of subjects: 0
Study 23631544 — intervention group
Group type: COMPARATOR
Intervention: Psychodynamic therapy
Number of subjects: 0
Study 20678841 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless extraction
Number of subjects: 27
Study 20678841 — intervention group
Group type: COMPARATOR
Intervention: Flap extraction
Number of subjects: 27
Study 18685141 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA (3 grams/day)
Number of subjects: 30
Study 18685141 — intervention group
Group type: COMPARATOR
Intervention: RASB (control)
Number of subjects: 30
Study 18685141 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA
Number of subjects: 30
Study 17101999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 162
Study 17101999 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 162
Study 17101999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 162
Study 17101999 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 162
Study 15364796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 4491
Study 15364796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4491
Study 11428270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 60
Study 11428270 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin + Gentamicin
Number of subjects: 60
Study 9531327 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunomycin-cytosine arabinoside with GM-CSF
Number of subjects: 318
Study 9531327 — intervention group
Group type: COMPARATOR
Intervention: Daunomycin-cytosine arabinoside
Number of subjects: 318
Study 8075874 — intervention group
Group type: EXPERIMENTAL
Intervention: maxEPA (eicosapentaenoic acid 0.178 g g‐1; docosahexaenoic acid 0.116 g g‐1) capsules 10 g per day for 28 days
Number of subjects: 27
Study 8075874 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 27
Study 8075874 — intervention group
Group type: EXPERIMENTAL
Intervention: maxEPA
Number of subjects: 27
Study 8075874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2583158 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated drink at a dose of 5 mg.kg‐1 body mass and at the 3rd and 5th h of marching an additional drink at a dose of 2.5 mg.kg‐1 body mass
Number of subjects: 23
Study 2583158 — intervention group
Group type: COMPARATOR
Intervention: Drink of equal volume
Number of subjects: 23
Study 5478 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally disturbed boys
Number of subjects: 40
Study 5478 — intervention group
Group type: COMPARATOR
Intervention: Normal boys
Number of subjects: 40
Study 5478 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with external locus of control
Number of subjects: 40
Study 5478 — intervention group
Group type: EXPERIMENTAL
Intervention: High anxious subjects
Number of subjects: 40
Study 5478 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally disturbed children classified as overanxious
Number of subjects: 40
Study 5478 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and locus of control
Number of subjects: 40
Study 31682542 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus carboplatin plus pemetrexed
Number of subjects: 345
Study 31682542 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib alone
Number of subjects: 345
Study 30921221 — intervention group
Group type: EXPERIMENTAL
Intervention: homemade sheathless technique
Number of subjects: 1
Study 30921221 — intervention group
Group type: COMPARATOR
Intervention: systemic nitroglycerin
Number of subjects: 1
Study 30921221 — intervention group
Group type: COMPARATOR
Intervention: glonoin and verapamil
Number of subjects: 1
Study 28282221 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture with collagen augmentation (group 2)
Number of subjects: 28
Study 28282221 — intervention group
Group type: COMPARATOR
Intervention: Microfracture alone (group 1)
Number of subjects: 28
Study 26485914 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenyang Huazhuo Tongluo Recipe (WYHZTLR) plus methotrexate (MTX) and prednisone for 6 months
Number of subjects: 82
Study 26485914 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (control) with methotrexate (MTX) and prednisone for 6 months
Number of subjects: 82
Study 23713303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticking needling group
Number of subjects: 288
Study 23713303 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 288
Study 21487312 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RES) - 60 minutes, 2 sets of 8 repetitions at 80% 1RM
Number of subjects: 10
Study 21487312 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AER) - 60 minutes of cycling at 70% of VO2peak
Number of subjects: 10
Study 21487312 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - resting condition
Number of subjects: 10
Study 19228851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl‐Meyer Assessment (FMA)
Number of subjects: 57
Study 19228851 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT)
Number of subjects: 57
Study 19228851 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) functional ability scores
Number of subjects: 57
Study 19228851 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) performance time score
Number of subjects: 57
Study 19228851 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) performance time scores
Number of subjects: 57
Study 16520168 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with perioperative myocardial ischemic injury (PMII)
Number of subjects: 236
Study 16520168 — intervention group
Group type: COMPARATOR
Intervention: Patients without perioperative myocardial ischemic injury (PMII)
Number of subjects: 236
Study 16520168 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PMII
Number of subjects: 236
Study 16520168 — intervention group
Group type: COMPARATOR
Intervention: Patients without PMII
Number of subjects: 236
Study 16520168 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk open vascular operations
Number of subjects: 236
Study 12627000 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSV with helium/oxygen (He/oxygen)
Number of subjects: 123
Study 12627000 — intervention group
Group type: COMPARATOR
Intervention: NIPSV with air/oxygen
Number of subjects: 123
Study 10381799 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 61753 (10 mg p.o.)
Number of subjects: 0
Study 10381799 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 61753 (0.1‐3.2 mg i.pl.)
Number of subjects: 0
Study 10381799 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 61753 (1.6 mg)
Number of subjects: 0
Study 10381799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9007598 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy (1 g intravenously every 8 hours)
Number of subjects: 94
Study 9007598 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g every 8 hours) plus metronidazole (0.5 g intravenously every 8 hours) for 5 to 10 days
Number of subjects: 94
Study 9007598 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy
Number of subjects: 94